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The MicraTM (Medtronic USA) Transcatheter Pacing System 
(TCP) is a 0.8 cm3, 2.0 grams self-contained unit that has the 
pulse generator, sensing and pacing electrodes fully contained 
within a single unit.(14) The device is 25.9mm long and has 
an outer diameter of 6.7mm(14) (Figure 1b). This device is 
delivered via a catheter through the femoral vein and is directly 
implanted inside the right ventricle of the heart where it is 
BACKGROUND
Cardiac pacemakers have been in clinical practice for more 
than 60 years. They remain the only treatment for sympto-
matic life-threatening bradycardias(1,2) and improve quality of 
life and survival.(3-5) Currently, more than 700 000 pacemakers 
are implanted around the world annually.(6) The annual inci-
dence of pacemaker implantations is increasing, particularly in 
older people.(7,8) A conventional cardiac pacemaker consists of 
a pacemaker generator containing the electronics and battery 
implanted in a subcutaneous pocket in the pectoral region and 
one or more leads connecting the generator to the heart 
(Figure 1a).(9,10) Conventional cardiac pacemakers are asso-
ciated with a 12.4% risk of acute complications.(11) These are 
due to pocket hematomas, pocket infections, pneumothorax/
haemothorax and many others.(10,11) In experienced hands, the 
complication rates are as low as 4%.(12) In addition, chronic 
complications related to transvenous leads like lead infection, 
lead malfunction, venous thrombosis and obstruction, are not 
uncommon.(10,11,13) Thus, there is a need for a cardiac pacing 
system that overcomes the pocket and lead-related compli-
cations of conventional cardiac pacing.
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Background: Cardiac pacemakers improve survival and 
quality of life in patients with atrioventricular (AV) 
block. However, conventional pacemakers carry a small 
risk of both acute and chronic lead and pacemaker 
generator complications. Leadless pacemakers negate 
these risks by not having a pacing lead and a sub-
cutaneous generator. We report our Groote Schuur 
Hospital experience with the Medtronic Micra trans-
catheter pacing system (TPS). 
Methods: We report a consecutive case series of 
patients that received the Micra leadless pacemaker. 
The Micra transcatheter pacemaker, a single chamber 
ventricular pacemaker, is inserted using a TPS via the 
femoral vein into the right ventricle. Implantation data 
were obtained, and medical records were reviewed for 
the 6 weeks and 1-year follow-up visits.
Results: A total of 5 patients were implanted with a 
Micra leadless pacemaker from 11 March 2015 - 
2 November 2016. Four patients were male and 1 
female, with an average age of 64 years. Four patients 
received the pacemaker for a second- or third-degree 
AV block and 1 patient received the pacemaker for 
unexplained syncope and right bundle branch block. 
The Micra leadless pacemaker was successfully 
implanted in all patients with no acute implantation-
related complications. One-year follow-up was available 
for 4 patients with good pacing thresholds, sensitivity 
and impedance. One patient demised after 9 months 
post Micra implantation due to unrelated causes (acute 
myeloid leukaemia).
Conclusion: The Micra leadless pacing system is safe 
and effective and shows good short-term results in a 
real-world, resource-limited setting. This form of pacing 
offers a viable option for patients who require pacing 
for AV block, especially in patients with vascular access 
problems or who are at high risk of lead or pacemaker 
generator complications.  SAHeart 2020;17:194-199
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fixed by nitinol tines.(9) The MicraTM was designed to negate 
the complications related to conventional pacemakers, i.e. 
pocket and lead-related problems. Prospective studies have 
shown good safety and performance endpoints of the MicraTM 
in patients that require permanent pacemaker implantation 
with very low adverse events. Herein we present a case series 
of the first MicraTM leadless pacemakers to be implanted in 
South Africa. 
METHODS
Consecutive patients implanted with a MicraTM from 1 January 
2015 - 31 December 2016 were included. All the devices were 
implanted in the Department of Medicine, Division of 
Cardiology at Groote Schuur Hospital. The MicraTM was 
delivered into the right ventricle with a deflectable delivery 
catheter via a 23 French internal diameter/27 French outer 
diameter femoral sheath in the right femoral vein (Figure 2a). 
The sheath is advanced using a guidewire and a dilator into 
the right atrium.(15) The guidewire and dilator are then 
removed and a steerable delivery system catheter with the 
MicraTM preloaded and tethered is then advanced into the 
right ventricle (Figure 2b).(15) The MicraTM is deployed by 
retraction of the device containing cup at the distal end of the 
delivery catheter positioned against the right ventricular endo-
cardium and is fixed into the myocardium by protraction of 
nitinol tines. Once the device is placed in the right ventricle 
and adequate fixation is confirmed, sensitivity, pacing thresh-
olds and impedance are measured.(15) 
RESULTS 
A total of five patients had the MicraTM implanted. The 
indications for MicraTM implantation were complete heart block 
in a patient with previous pocket sepsis, lead malfunction in a 
patient with superior vena cava obstruction with complete 
heart block, symptomatic 2:1 atrioventricular (AV) block, 
symptomatic Mobitz 1 AV block, and, lastly, a patient with right 
bundle branch block and first-degree AV block presenting 
with syncope (Table 1). The MicraTM was successfully implanted 
in all 5 patients via the right femoral vein. All patients had a 
1-year follow-up, except for patient number 4 who died 
before his 1-year follow-up from Acute Myeloid Leukemia 
(AML). All the other patients were clinically well at 1-year 
follow-up post MicraTM implantation. 
The ranges of ventricular pacing thresholds at implantation, 6 
weeks and 1 year were 0.25 - 0.75V, 0.38 - 0.5V and 0.38 - 
0.75V (all with a pulse width of 0.24ms) respectively (Figure 3). 
The ranges of R wave amplitudes at implantation, 6 weeks 
and 1 year were 11.4 - 20mV, 4.8 - 20mV and 16 - 18.1mV 
respectively (Figure 5). The ranges of pacing impedances at 
implantation, 6 weeks and 1 year were 690 - 970Ω, 530 - 810Ω 
and 550 - 670Ω respectively (Figure 4).
FIGURE 1: (A) Chest radiograph of a patient with a conventional pacemaker, white arrows indicates pacemaker lead extending from the 
generator (white circle) to the right ventricular apex. (B) Chest radiograph of a patient with a MicraTM in the right ventricular apex (yellow circle). 
A B
196
There were no acute or chronic implantation-related com-
plications.
DISCUSSION 
Ever since the first fully implantable cardiac pacemaker was 
implanted in 1958, the shortcomings of conventional pacing 
secondary to pocket and lead-related complications have been 
evident.(16) Investigational work on a miniaturised fully im-
plantable cardiac pacemaker started as early as the 1970s.(17,18) 
More than 30 years later, leadless and miniaturised cardiac 
pacing has become clinically available. 
Three of the 5 patients included in this series were inserted as 
part of the Micra transcatheter Pacing study, which was a 
prospective, non-randomised single-study group multicentre 
landmark study to evaluate safety and efficacy of this new 
technology. In brief, 725 patients with a class I or class II 
indication for cardiac pacing and who were considered suit-






FIGURE 2: (A) The white arrow depicts a 27 French outer diameter sheath in the inferior vena cava via the right femoral vein. (B) The yellow 
arrow depicts a steerable delivery catheter with MicraTM preloaded (black arrow). (C) MicraTM is deployed in the right ventricle apex by 













were implanted with a Micra TPS.(19) The device was success-
fully implanted in 99.2% of the patients. These patients 
achieved a 96% freedom from major complications (95% 
Confidence Interval [CI], 93.9 - 97.3; p <0.001) and this was 
statistically significant when compared with the safety per-
formance goal of 83%.(19) These investigators defined primary 
efficacy as the percentage of patients with low thresholds 
and stable pacing capture at 6 months (≤2.0V at 0.24ms and 
an increase of ≤1.5V from implantation). The rate of primary 
efficacy was 98.3% (95% CI, 96.1 - 99.5; p <0.001 when com-
TABLE I: Clinical details and indications for a permanent pacemaker.
Patient No No 1 No 2 No 3 No 4 No 5
Date of Birth 7 September 1934 14 August 1955 9 July 1951 16 April 1941 2 August 1970
Age (years) 80 61 64 73 46
Indication for PPM
RBBB, 1st degree AV 
block with Syncope 
Post AVR CHB
Symptomatic Mobitz 1 










Symptomatic Mobitz 1 

































Last Follow-up 17 April 2018 16 November 2017 13 September 2016 9 June 2015 8 December 2016
Months since Implantation 
Patient status Doing Well Doing Well Doing Well 
AML for Palliative Care
Demised 20/12/2015
Doing well
FIGURE 3: Micra thresholds at implantation, 6 weeks and 1 year.
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Pacing threshold
pared with the efficacy performance goal of 80%) among 292 
patients at 6 months.(19) These data confirmed the safety and 
efficacy of the Micra TPS at 6 months. Registry data have sub-
sequently confirmed the safety, efficacy and limited compli-
cation rates of the Micra TPS in the real world setting, with 
patient follow-up to 12 months.(20,21) 
In this case series, we report the first consecutive 5 patients 
implanted with a Micra TPS leadless pacemaker in South Africa. 
These patients represent the first patients to receive this 
ground-breaking technology in our country. The Micra TPS 
was successfully implanted in all patients. There were no 
implantation-related complications or device-related compli-
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cations at 1 year of follow-up. There was 1 death in this patient 
cohort, which was not related to device implantation. 
CONCLUSION
This small series of leadless pacemaker implantations con-
firms the safety and efficacy of the Micra TPS system in a 
resource-constraint setting over a 1-year follow-up period. A 
leadless pacemaker is a good option for patients who require 
pacing and who are at high risk of pocket or lead-related com-
plications or when conventional pacing is not possible.
Conflict of interest: none declared. 
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